Levomepromazin Neuraxpharm

Levomepromazine Hydrochloride, the active ingredient in Levomepromazin Neuraxpharm, is a phenothiazine antipsychotic presented as an injectable solution for intramuscular or intravenous use. It is employed to manage schizophrenia, severe agitation, nausea, vomiting and palliative sedation in appropriate patients under medical supervision and careful monitoring.

GNH USA supplies Levomepromazin Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through a robust quality‑assured distribution network. The company adheres to stringent regulatory standards and provides comprehensive technical support to its global partners.

Levomepromazine is a phenothiazine antipsychotic used in several clinical situations that involve dopamine blockade and related pathways.

Schizophrenia: reduces psychotic symptoms and stabilizes mood in patients with chronic disease. Severe agitation: provides rapid calming effect in acute psychiatric emergencies. Nausea and vomiting: controls chemotherapy‑induced or postoperative nausea when other agents are insufficient. Palliative sedation: induces sedation to alleviate refractory distress in end‑of‑life care.

Levomepromazine may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness: pronounced sedation and somnolence. - Orthostatic hypotension: dizziness upon standing due to vascular blockade. - Dry mouth: reduced salivation causing discomfort. - Constipation: slowed gastrointestinal motility.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever, rigidity, autonomic instability. - Torsades de pointes: rare ventricular arrhythmia linked to QT prolongation. - Severe extrapyramidal symptoms: acute dystonia, parkinsonism, or akathisia requiring immediate treatment.

When prescribing Levomepromazine, clinicians should observe several precautionary measures to minimize risks. - Cardiac assessment: obtain baseline ECG due to potential QT‑interval prolongation. - Blood pressure monitoring: watch for orthostatic hypotension, especially after dose changes. - Hepatic/renal evaluation: consider dose adjustment in patients with organ impairment. - Hypersensitivity check: avoid use in individuals with known allergy to phenothiazines. - Elderly caution: increased susceptibility to sedation, falls, and anticholinergic effects. - Store below 25°C: keep in original container, protect from light and moisture.

Levomepromazine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - QT‑prolonging drugs (e.g., macrolide antibiotics, antiarrhythmics) may increase risk of torsades de pointes. - CNS depressants (e.g., benzodiazepines, opioids) can cause excessive sedation or respiratory depression. - Anticholinergic agents may exacerbate dry mouth and constipation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) may raise levomepromazine plasma levels. - Antihypertensive agents may have additive hypotensive effect. - Lithium may increase neurotoxic risk when combined with antipsychotics.